News
Keep up to date with our business activities by reading our news.
10 November 2025
Ascend Unveils Proprietary Enhancers That Significantly Improve AAV Yields Without Compromising Quality
New data from Ascend’s R&D team demonstrate up to 3-fold increase in AAV yields supporting greater efficiency and scalability...
Read More5 November 2025
Ascend Advanced Therapies Identifies microRNAs That Enhance AAV Vector Production
Screen of more than 2,400 microRNAs identifies multiple candidates that significantly enhance vector productivity without compromising quality attributes. Munich,...
Read More8 October 2025
European Patent on Ascend Advanced Therapies’ EpyQ® AAV Plasmid Technology Successfully Defended at the EPO
Rockville, Maryland – 8th October, 2025 – Ascend Advanced Therapies (Ascend), a gene-to-GMP development partner, today announced that its...
Read More10 June 2025
Ascend Completes GMP Certification for Quality Control Testing in Munich Facility
Rockville, Maryland – 10 June 2025 – Ascend Advanced Therapies (Ascend), a gene-to-GMP development partner, has received GMP certification...
Read More5 March 2025
Ascend Advanced Therapies Appoints John Chiminski as Chair & Karen Flynn as Independent Director
Rockville, MD – March 5, 2025 – Ascend Advanced Therapies (Ascend), a gene to GMP advanced therapy development partner,...
Read More12 November 2024
Ascend Advanced Therapies Partners with EW Healthcare Partners to Expand United States Capacity and Capabilities
London, United Kingdom – 12 November 2024 – Ascend Advanced Therapies (Ascend), a gene-to-GMP development partner, has partnered with...
Read More4 October 2024
AST places next generation of flexible, isolated Fill-Finish system at Ascend Alachua facility for AAV production
The team is thrilled to partner with AST on a customized filling line that is being built for placement...
Read More24 September 2024
Continued Investment in Technology & Flexible Capacity, Including New Fill/Finish Capabilities, Fortify the Global Gene Therapy Support Offer at Ascend
London, United Kingdom – 24 September 2024 – Ascend Advanced Therapies (Ascend), a gene to GMP development partner, has...
Read More28 August 2024
Ascend Strengthens Operations with Two New Executive Team Hires
London, United Kingdom – 28 August 2024 – Ascend Advanced Therapies (Ascend), an end-to-end gene therapy development partner has...
Read More24 April 2024
Ascend hires Scott Law as COO and continues strengthening foundation
London, United Kingdom, 24 April 2024 – Ascend Advanced Therapies (Ascend), an end-to-end gene therapy development partner, has announced...
Read More9 April 2024
Ascend acquires GMP manufacturing capacity in Alachua, Florida from Beacon Therapeutics
London, United Kingdom, 9 April 2024 – Ascend Advanced Therapies (Ascend), an end-to-end gene therapy development partner, has acquired...
Read More27 March 2023
Mike Stella announced as the successor to founding CEO, Tim Funnell
Ascend Advanced Therapies launched out of stealth mode with a fundraise of over $130M in early 2023. Shortly thereafter,...
Read More